Evidence map›Paper›PMID 41256157›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Quantifying the number of people who would benefit from HIV pre-exposure prophylaxis (PrEP) in the United States: a comparison of behavioral, acquisition-risk based, and economic metrics.

Minttu M Rönn, Athena P Kourtis, Yizhi Liang, Lijia Zheng, Teresa Puente, Ya-Lin A Huang, Weiming Zhu, Rupa R Patel, Jeffrey Wiener, Karen W Hoover and 3 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Minttu M RönnDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, United States.ORCID 0000-0002-9292-5670
Athena P KourtisDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Yizhi LiangDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, United States.
Lijia ZhengDepartment of Health Policy, Stanford University School of Medicine, United States.
Teresa PuenteDepartment of Health Policy, Stanford University School of Medicine, United States.
Ya-Lin A HuangDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Weiming ZhuDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Rupa R PatelDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Jeffrey WienerDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Karen W HooverDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Michelle Van HandelOffice of Director, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Nicolas A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, United States.
Joshua A SalomonDepartment of Health Policy, Stanford University School of Medicine, United States.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

Purpose: We developed metrics to estimate the number of people who could benefit from PrEP using clinical, behavioral, and economic considerations. Methods: We estimated the distribution of annual HIV acquisition risk in the U.S. population and the number who would benefit from PrEP based on HIV acquisition risk thresholds. Estimates were generated for men who have sex with men (MSM), men who have sex with women (MSW), women who have sex with men (WSM), and people who inject drugs (PWID). Populations were stratified by state, age, and race and ethnicity. Adult PWID were stratified by state and sex. We also derived a measure anchored on a willingness-to-pay threshold to gain one quality-adjusted life year (QALY). Results: We estimated 31-57% of MSM could benefit from PrEP by HIV acquisition risk thresholds, and 30% when using the cost-per-QALY threshold. For PWID, estimates ranged from 7% (cost-per-QALY) to 60% (highest risk threshold). MSW and WSM had the lowest proportions estimated to benefit (0-11%), but the absolute number of individuals remained large due to the size of these populations. Discussion: These estimates provide a broader framework in which to examine need for PrEP at the population and program level in the United States.

Indexed as

HIVHIV preventionPre-exposure prophylaxis

Identifiers

PMID41256157
PMCPMC12622065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.